This site is intended for healthcare professionals

Draft NICE guidance does not recommend Piqray + fulvestrant for metastatic breast cancer with PIK3CA mutation.- Novartis

Read time: 1 mins
Published:4th Apr 2022

In a draft recommendation, the UK National Institute for Health and Care Excellence (NICE) has decided not to recommend Piqray (alpelisib), from Novartis, for use in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor positive(HR+), human epidermal growth factor receptor 2 negative (HER2-), locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine-based therapy.

Condition: Breast Cancer HER2-
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.